Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633386 · ClinicalTrials.gov registry record · Phase 4
Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery
A Phase 4 study of Arthroscopy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT00633386 is a Phase 4 study of Arthroscopy that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 200 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT00633386, a Phase 4 study of Arthroscopy, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Celecoxib
Study Locations (9)
Arizona
- Pfizer Investigational Site - Phoenix
Florida
- Pfizer Investigational Site - St. Petersburg
Maryland
- Pfizer Investigational Site - Baltimore
Massachusetts
- Pfizer Investigational Site - Springfield
Missouri
- Pfizer Investigational Site - Springfield
South Carolina
- Pfizer Investigational Site - Columbia
Tennessee
- Pfizer Investigational Site - Johnson City
Texas
- Pfizer Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633386
The ClinicalTrials.gov registry entry for NCT00633386 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthroscopy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633386 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00633386 about?
NCT00633386 is a clinical study titled "Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery". To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
What is the current status of trial NCT00633386?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2003-02. Estimated completion is 2003-08.
What conditions does trial NCT00633386 study?
This clinical trial studies the following conditions: Arthroscopy.
What interventions are being tested in trial NCT00633386?
The interventions under investigation include: Placebo (OTHER), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00633386?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633386 being conducted?
This trial has 9 study locations across Arizona, Florida, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthroscopy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.